2 days Ago By ABMN Staff
Arvinas ( NASDAQ:ARVN – Free Report ) had its price objective lowered by BMO Capital Markets from $90.00 to $88.00 in a report issued on Wednesday morning, Benzinga reports.
The firm currently has an outperform rating on the stock. Other analysts have also issued reports about the company. Stephens started coverage on Arvinas in a research note on Monday, November 18th.
They set an “overweight” rating and a $55.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a report on Monday, September 9th.
HC Wainwright restated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Thursday, October 31st. Wedbush reaffirmed an “outperform” rating and issued a $57.
00 price target on shares of Arvinas in a report on Tuesday, July 30th. Finally, Oppenheimer dropped their price objective on Arvinas from $50.00 to $40.
00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.08. View Our Latest Stock Analysis on Arvinas Arvinas Stock Performance Arvinas ( NASDAQ:ARVN – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 30th.
The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.
20. The company had revenue of $102.40 million during the quarter, compared to analysts’ expectations of $60.
56 million. Arvinas’s quarterly revenue was up 196.0% compared to the same quarter last year.
During the same period last year, the firm posted ($1.18) earnings per share. On average, equities analysts forecast that Arvinas will post -3.
32 earnings per share for the current year. Institutional Trading of Arvinas A number of hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in Arvinas in the third quarter worth $39,000.
Quest Partners LLC purchased a new stake in Arvinas during the 2nd quarter valued at $42,000. Amalgamated Bank grew its holdings in Arvinas by 29.6% in the 2nd quarter.
Amalgamated Bank now owns 2,223 shares of the company’s stock worth $59,000 after acquiring an additional 508 shares during the last quarter. Mirae Asset Global Investments Co. Ltd.
increased its position in shares of Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co.
Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares during the period. Finally, Quantbot Technologies LP raised its stake in shares of Arvinas by 147.
3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Institutional investors own 95.
19% of the company’s stock. About Arvinas ( Get Free Report ) Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Stories Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter ..
